Chronic Myeloproliferative Disorders Completed Phase 2 Trials for Cyclophosphamide (DB00531)

IndicationStatusPhase
DBCOND0028462 (Chronic Myeloproliferative Disorders)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00053989Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic AnemiaTreatment
NCT00134017Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic CancerTreatment
NCT00002792Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative DisordersTreatment
NCT00004181Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid MetaplasiaTreatment
NCT00006379Non-Ablative Allo HSCT For Hematologic Malignancies or SAATreatment
NCT00005804Bone Marrow Transplantation in Treating Patients With Hematologic CancerTreatment
NCT00005797Bone Marrow Transplant in Treating Patients With Hematologic CancersTreatment
NCT00005622Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic DisordersTreatment
NCT00134004Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic CancerTreatment
NCT00445900Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid MetaplasiaTreatment
NCT00589563Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological CancerSupportive Care